Answer from: Medical Oncologist at Academic Institution
The BRUIN trial did not recommend upfront dose reduction for pirtobrutinib in patients who were exposed to cBTKi before. For patients who we think are still appropriate for BTK inhibitor therapy, we typically start with the full dose of pirtobrutinib in our practice. However, patients who experience...